Nathalie Adda - Nov 1, 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Nov 1, 2021
Transactions value $
-$347,199
Form type
4
Date filed
11/2/2021, 08:33 PM
Previous filing
Oct 13, 2021
Next filing
Nov 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $463K +9.55K +35.43% $48.52 36.5K Nov 1, 2021 Direct
transaction ENTA Common Stock Sale -$165K -1.95K -5.35% $84.31 34.5K Nov 1, 2021 Direct F1, F2
transaction ENTA Common Stock Sale -$637K -7.5K -21.7% $85.02 27K Nov 1, 2021 Direct F1, F3
transaction ENTA Common Stock Sale -$8.62K -100 -0.37% $86.21 26.9K Nov 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -9.55K -40.63% $0.00 14K Nov 1, 2021 Common Stock 9.55K $48.52 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.74 to $84.73, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.74 to $85.63, inclusive.
F4 The option, representing a right to purchase a total of 23,500 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017).

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 above.